Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,444.76
(
1.59%
)
US TECH 100
22,715.20
(
1.72%
)
Dow Jones
45,754.73
(
1.19%
)
Brent Oil
106.36
(
-2.04%
)
Bitcoin
67,602.99
(
1.35%
)
News Focus
News Focus
Post# of 257318
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122827
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Mufaso post# 250081

Monday, 01/08/2024 6:32:22 PM

Monday, January 08, 2024 6:32:22 PM

Post# of 257318
PFE has an oral *non*-GLP-1 anti-obesity drug in phase-1, according to today’s JPM webcast. For competitive reasons, PFE is not disclosing the MoA. (I am not referring to PF-06954522, which is an oral GLP-1 in phase-1.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up